Asian Spectator

Times Advertising

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

HONG KONG SAR - Media OutReach - 26 April 2023 - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that Phase III clinical trial of SinoMab's flagship product SM03 (Suciraslimab) for rheumatoid arthritis (RA) in China (Study No.

Magazine

Why Contractors Suction Hose Solutions Are Essential For Heavy-Duty Fluid Handling

In industries where materials move as relentlessly as time itself, equipment must match that intensity. Whether on construction sites, agricultural operations, or large-scale industrial setups, flui...

Aksi seksisme di ruang digital memiliki pola tersendiri yang bisa kita pahami

Seksime di internet sering kali dianggap sepele karena dianggap sekadar komentar-komentar buruk maupun lelucon yang kasar yang sayangnya kerap dimaklumi sebagai candaan semata. Namun, apa yang tampakn...

Bukan hanya pemilik mobil mewah, dampak kenaikan harga BBM nonsubsidi bakal dirasakan semua orang

● Para pengguna pertamax turbo dan solar nonsubsidi harus gigit jari karena kenaikan harganya sangat tinggi.● Kenaikan harga ini seolah hanya berdampak pada kalangan menengah ke atas.χ...